Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. reported 2025 results showing a smaller overall loss alongside a major strategic shift toward its ChemPass AI generative small‑molecule platform. Net loss for 2025 narrowed to approximately $7.8 million from about $18.1 million, mainly due to lower operating expenses and a $6.4 million gain on the sale of Lavie Bio and MicroBoost AI for Ag to ICL, recorded in $5.7 million of income from discontinued operations.
Full‑year revenues fell to roughly $3.9 million from $5.6 million as certain AgPlenus and Corteva revenues and Casterra seed sales declined. A $2.2 million Casterra inventory impairment pushed 2025 cost of revenues to about $4.1 million, driving an operating loss of $14.0 million. Cash, cash equivalents and short‑term deposits were about $13.0 million at year‑end, after using $13.5 million in operating cash during 2025, while management exited non‑core assets, resized the organization and highlighted new AI collaborations with Google Cloud in pharma and agriculture.
Evogene Ltd. is outlining a strategic transformation centered on its ChemPass AI™ computational chemistry engine. After reassessing its technology and capital allocation in 2025, the company chose to focus resources on designing small molecules for two core markets: human health therapeutics and agricultural chemicals.
Evogene consolidated activity around ChemPass AI™, discontinued non-core work, divested misaligned subsidiaries, resized its organization and built a business development team aligned with this focused strategy. The platform operates on a 38‑billion‑molecule universe, aiming to generate novel, highly active, synthesizable compounds that meet complex multi‑parameter development requirements from the outset.
The company highlights collaborations in human health with biotechnology and academic partners, and in agriculture through its AgPlenus subsidiary, including relationships with Bayer and Corteva. It reports completion of key divestments, such as Lavie Bio’s sale to ICL and licensing of Biomica’s lead oncology candidate to Lishan Pharmaceuticals, while retaining exposure to assets like Casterra.
Evogene Ltd. entered a warrant inducement agreement with an existing institutional investor, leading to the cash exercise of 3,384,616 existing warrants at a reduced exercise price of $1.00 per share for approximately $3.4 million in gross proceeds. In return, Evogene will issue 5,076,924 new Series A-1 and Series B-1 warrants with a $1.25 exercise price, five-year and 18‑month terms, and a 4.99% ownership cap. The company plans to use the net proceeds for working capital and general corporate purposes and will seek to register the resale of shares underlying the new warrants on a Form F‑3. Evogene agreed to short-term restrictions on issuing additional equity or entering variable rate transactions, with limited exceptions including a potential at‑the‑market program via its advisor, A.G.P./Alliance Global Partners.
Evogene Ltd. reports that its subsidiary Biomica has granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license for BMC128, a microbiome-based therapy designed to enhance anti-tumor immune activity in renal cell carcinoma and non-small cell lung cancer.
Lishan Biotech will lead global clinical development, manufacturing and commercialization of BMC128, which is completing a Phase 1 study and has shown an excellent safety profile with early signs of efficacy, including many patients with previously progressive disease achieving stable disease. Biomica is eligible for development and sales milestone payments and royalties on future commercial sales under the agreement.
Evogene Ltd. reports a planned change in its senior finance leadership. Chief Financial Officer Yaron Eldad will resign effective March 31, 2026, for personal reasons, and the company states there was no disagreement regarding its operations, policies, or practices. VP Finance Polina Ravzin, who has served in that role since 2022 and previously held finance positions at DSIT Solutions Ltd. and Acorn Energy Inc., will continue as VP Finance while also taking on CFO responsibilities.
Evogene Ltd. submitted a Form 6-K announcing that it has released its financial results for the third quarter ended September 30, 2025. The company also scheduled a conference call on November 20, 2025 to discuss these quarterly results and made an investor slide presentation available.
The third quarter 2025 financial results are provided in a press release attached as Exhibit 99.1, and the accompanying slide deck is attached as Exhibit 99.2. The GAAP financial statement tables in the press release are incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so they now form part of those registration materials from the date of this Form 6-K.
Evogene Ltd. furnished its unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six-month period ended June 30, 2025. The filing lists interactive data files for consolidated interim statements of financial position, profit or loss, changes in equity, cash flows and notes. Exhibits 99.1 and 99.2 are incorporated by reference into the company’s registration statements on Form F-3 and Form S-8 and will form part of those filings to the extent not later superseded. The Form 6-K is signed by the CFO and serves to furnish interim financial reporting and management commentary for the first half of 2025.
Evogene Ltd. submitted a Form 6-K to provide investors with materials related to its second quarter 2025 results. The company states that it announced financial results for the quarter ended June 30, 2025, and furnished the full press release as an exhibit to this report.
Evogene also notes that it is holding a conference call on August 19, 2025 to discuss its quarterly results and has prepared a slide presentation for that call. Both the press release and the slide deck are attached as exhibits and incorporated by reference, and the GAAP financial statement tables in the press release are incorporated into certain existing Form F-3 and Form S-8 registration statements.